Impact of Different Prevention Strategies on Neonatal Group B Streptococcal Disease

ABSTRACT

The objective of this paper is to evaluate the effect of different prevention strategies on the rate of early-onset neonatal group B streptococcus (GBS) disease and mortality. We compared the neonatal mortality and morbidity rates associated with early-onset GBS disease in three periods characterized by different prevention strategies, including no screening for GBS during pregnancy and no standardized chemoprophylaxis (1/1987 to 12/1990), antibiotic prophylaxis only with risk factors for GBS (1/1991 to 12/1994), and universal screening for GBS with rectovaginal cultures and chemoprophylaxis for women with positive results or risk factors (1/1995 to 12/1999). Statistical analysis included Fisher's exact test and Chi-square, with a two-tailed p <0.05 considered significant. The yearly prevalence of positive GBS cultures was similar throughout the screening period (mean 18%, range 16 to 19%). Compared with the no prophylaxis group (rate = 4/8,573), introduction of universal screening (rate = 0/13,754, p = 0.02) but not of prophylaxis for risk factors alone (rate = 1/10,303, p = 0.18) significantly decreased the occurrence of GBS-specific neonatal mortality. Universal screening decreased, though not significantly, the GBS-specific neonatal morbidity rates compared with a policy based on risk factors alone (0.4/1000 vs. 0.8/1000, p = 0.29). Our study had a power to detect a 0.7/1000 difference in the rate of specific morbidity between the two chemoprophylaxis policies (α = 0.05, β= 0.80). Intrapartum prophylaxis for GBS, using universal screening or risk factors, is associated with a significant reduction in the specific neonatal mortality rate compared with no prophylaxis. Universal screening for GBS leads to a decrease in specific GBS morbidity compared with screening using risk factors alone.

KEYWORDS

Group B streptococcus - neonatal sepsis - antibiotic prophylaxis - screening - risk-based approach

REFERENCES

• 1 Schrag S J, Zywicki S, Farley M M. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.  N Engl J Med . 2000;  342 15-20
• 2 Beardsall K, Thompson M K, Mulla R J. Neonatal group B streptococcal infection in South Befordshire, 1993-1998.  Arch Dis Child Fetal Neonatal Ed . 2000;  82 F205-F207
• 3 Embleton N, Wariyar U, Hey E. Mortality from early onset group B streptococcal infection in the United Kingdom.  Arch Dis Child Fetal Neonatal Ed . 2000;  80 F139-F141
• 4 Kieran E, Matheson M, Mann A G, Efstratiou A A, Butler K, Gorman W. Group B streptococcus (GBS) colonization among expectant Irish mothers.  Ir Med J . 1998;  91 21-22
• 5 Juncosa T, Bosch J, Dopico E. Neonatal infection by streptococcus agalactiae: multicenter study in the area of Barcelona, Spain.  Enferm Infec Microbiol Clin . 1998;  16 312-315
• 6 Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: a public health perspective (published erratum appears in MMWR Morb Mortal Wkly Rep 1996;45:679).  MMWR Mort Wkly Rep . 1996;  45 RR-7:1-24
• 7 Main E K, Slagle T. Prevention of early-onset invasive neonatal group B streptococcal disease in a private hospital setting: the superiority of culture-based protocols.  Am J Obstet Gynecol . 2000;  182 1344-1354
• 8 Locksmith G J, Clark P, Duff P. Maternal and neonatal infection rates with three different protocols for prevention of group B streptococcal disease.  Am J Obstet Gynecol . 1999;  180 416-422
• 9 American College of Obstetricians and Gynecologists. Prevention of early-onset group B streptococcal disease in newborns.  Committee Opinion . 1996;  173
• 10 Boyer K M, Gotoff S P. Prevention of early onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis.  N Engl J Med . 1986;  314 1665-1669
• 11 American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis.  Pediatrics . 1992;  90 775-778
• 12 Dillon H C, Gray E, Pass M A, Gray B M. Anorectal and vaginal carriage of group B streptococci during pregnancy.  J Infect Dis . 1982;  145 794-799
• 13 Tuppurainen N, Hallman M. Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients.  Obstet Gynecol . 1986;  73 583-587
• 14 Gotoff S P, Boyer K M. Prevention of group B streptococcal early onset sepsis: 1989.  Pediatr Infect Dis J . 1989;  8 268-270
• 15 Rouse D J, Goldenberger R L, Cliver S P, Cutter G R, Mennemeyer S T, Fargason C A. Strategies for the prevention of early-onset neonatal group B streptococcal sepsis: a decision analysis.  Obstet Gynecol . 1994;  83 483-494
• 16 Hafner E, Sterniste W, Rosen A. Group B streptococci during pregnancy: a comparison of two screening and treatment protocols.  Am J Obstet Gynecol . 1998;  179 677-681
• 17 Gibbs R S. Strategies for prevention of infection with group B streptococci [letter].  Am J Obstet Gynecol . 1999;  181 767
• 18 Gibbs R S, McDuffie R S, McNabb F, Fryer G E, Miyoshi T, Merenstein G. Neonatal group B streptococcal sepsis during 2 years of a universal screening program.  Obstet Gynecol . 1994;  84 496-500
• 19 Katz P F, Hibbard J U, Ranganathan D, Meadows W, Ismail M. Group B streptococcus: to culture or not to culture?.  J Perinatol . 1999;  19 337-342
• 20 Towers C V, Suriano K, Asrat T. The capture rate of at-risk term newborns for early-onset group B streptococcal sepsis determined by a risk factor approach.  Am J Obstet Gynecol . 1999;  181 1243-1249
• 21 Hager W D, Shuchat A, Gibbs R, Sweet R, Mead P, Larsen J W. Prevention of perinatal group B streptococcal infection: current controversies.  Obstet Gynecol . 2000;  96 141-145
• 22 Towers C V, Carr M H, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin.  Am J Obstet Gynecol . 1998;  179 879-883